Tamiflu could halve pandemic flu death toll: study

Related Topics

A pharmacist displays Swiss drug maker Roche's Tamiflu bird flu anti-viral tablets at a pharmacy in Sarajevo, February 18, 2006. Using antiviral Tamiflu could halve the potential death toll from an influenza pandemic if it was used both to treat and prevent the disease, its maker Roche said on Friday. REUTERS/Danilo Krstanovic

A pharmacist displays Swiss drug maker Roche's Tamiflu bird flu anti-viral tablets at a pharmacy in Sarajevo, February 18, 2006. Using antiviral Tamiflu could halve the potential death toll from an influenza pandemic if it was used both to treat and prevent the disease, its maker Roche said on Friday.

Credit: Reuters/Danilo Krstanovic

GENEVA | Fri Jun 22, 2007 4:51am EDT

GENEVA (Reuters) - Using antiviral Tamiflu could halve the potential death toll from an influenza pandemic if it was used both to treat and prevent the disease, its maker Roche said on Friday.

Research presented by Beate Sander of the University of Toronto, Canada, showed a stockpile of Tamiflu sufficient to cover 65 percent of a country's population could cut deaths by approximately half, Roche said.

Tamiflu is seen as one of the best defenses against a possible bird flu pandemic. It is recommended by the World Health Organization as a first-line defense, and governments and are stockpiling the drug.

Some governments are now planning stockpiles sufficient to will allow them to provide Tamiflu preventatively to people who have been in close contact with infected individuals, Roche said.

"The reality is that country stockpiles of Tamiflu are limited and are targeted at treatment only rather than treatment and prevention," the Roche statement said.

"However, some governments are now planning for sufficient antiviral stockpiles that will allow them to provide Tamiflu preventatively to close contacts of infected individuals, it said."

Details were presented at an influenza conference in Toronto.

Related Quotes and News

Company
Price
Related News
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.